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There is limited data on the differences in F-wave characteristics between spinobulbar
muscular atrophy (SBMA) and lower motor neuron dominant (LMND) amyotrophic lateral
sclerosis (ALS). We compared the parameters of F-waves recorded bilaterally from the
median, ulnar, tibial, and deep peroneal nerves in 32 SBMA patients, 37 patients with
LMND ALS, and 30 normal controls. The maximum F-wave amplitudes, frequencies of
giant F-waves, and frequencies of patients with giant F-waves in all nerves examined
were significantly higher in the SBMA patients than in the ALS patients and the normal
controls. The mean F-wave amplitude, maximum F-wave amplitude, frequency of giant
F-waves, and frequency of patients with giant F-waves in the median and deep peroneal
nerves were comparable between the ALS patients and normal controls. Giant F-waves
were detected in multiple nerves and were often symmetrical in the SBMA patients
compared with the ALS patients. The number of nerves with giant F-waves seems to
be the most robust variable for differentiation of SBMA from ALS, with an area under
the curve of 0.908 (95% CI: 0.835–0.982). A cut-off value of the number of nerves with
giant F-waves (≥3) for diagnosing SBMA showed high sensitivity and specificity: 85%
sensitivity and 81% specificity vs. ALS patients. No significant correlations were found
between the pooled frequency of giant F-waves and disease duration in the SBMA
(r = 0.162, P = 0.418) or ALS groups (r = 0.107, P = 0.529). Our findings suggested
that F-waves might be used to discriminate SBMA from ALS, even at early stages of
disease.
Keywords: spinobulbar muscular atrophy, amyotrophic lateral sclerosis, F-wave, giant F-wave, nerve conduction
study, motor neuron
INTRODUCTION
X-linked recessive spinobulbar muscular atrophy (SBMA), or Kennedy’s disease, is a relatively
benign motor neuron disorder in which life expectancy is only slightly compromised (Chahin
et al., 2008). A considerable number of SBMA patients may have been misdiagnosed with other
neuromuscular diseases, such as amyotrophic lateral sclerosis (ALS) and progressive muscular
atrophy, because a family history is not always available for SBMA patients, and typical symptoms
of SBMA can be absent initially and appear later in the disease course (Parboosingh et al., 1997).
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In some ALS patients, upper motor neuron (UMN) signs appear
late in the disease course or not at all (Hama et al., 2012). It is
difficult to distinguish SBMA from ALS clinically, particularly
when patients lack the classic signs for these diseases. However,
it is important to differentiate between SBMA and ALS because
these two diseases have different prognosis.
Previous studies have demonstrated differences between
SBMA and ALS in sensory action potential amplitudes, needle
electromyography manifestations, cortical excitability testing,
serum creatine kinase levels, and clinical presentations (Ferrante
and Wilbourn, 1997; Hirota et al., 2000; Vucic and Kiernan, 2008;
Chahin and Sorenson, 2009; Hama et al., 2012; Jokela et al.,
2015). It has been suggested that the frequencies of giant F-waves
and repeater F-waves are significantly increased in patients with
anterior horn cell disorders compared with the healthy subjects
(Petajan, 1985; Ibrahim and el-Abd, 1997). However, differences
in the characteristics of F-waves between motor neuron diseases
such as SBMA and ALS have not been explored up till now. In
particular, the relationship between the duration of motor neuron
disease and the frequency of giant F-waves has not been explored.
The goal of our study was to compare F-wave characteristics
between SBMA and lower motor neuron dominant (LMND) ALS
to investigate the clinical value of F-waves for discriminating
SBMA from LMND ALS.
MATERIALS AND METHODS
Participants
A total of 32 SBMA patients and 37 LMND ALS patients
were recruited consecutively for this study between August 2013
and July 2014. Concentric needle electromyography recordings
showed evidence of widespread acute and chronic motor axon
loss in both the SBMA and ALS patients. All of the SBMA
patients included in this study were clinically and genetically
diagnosed with SBMA before entrance into the study (Brooks
and Fischbeck, 1995). The age at disease onset was defined
for both the SBMA patients and the ALS patients as the
age at which the patient first noted motor manifestations,
including muscle weakness, atrophy, dysphagia, or dysarthria.
For the SBMA patients, gynecomastia, occasional fasciculation,
paresthesias, or dysesthesias were not used to determine the
disease onset, because these manifestations frequently appear
long before the neuromuscular manifestations. Lower motor
neuron (LMN) involvement was the predominant finding at
examination in all of the ALS patients. All of the ALS
patients met the El Escorial World Federation of Neurology
criteria for the diagnosis of probable laboratory-supported,
probable, or definite ALS during follow-up for 1–2 years.
No exaggeration of deep tendon jerks in the limbs of ALS
patients could minimize the effect of enhanced monosynaptic
reflexes on F-wave amplitude (Ibrahim et al., 1993). We
clinically staged the ALS patients using the revised ALS
Functional Rating Scale (ALSFRS-R) score (Cedarbaum et al.,
1999). Using the Medical Research Council (MRC) score, we
assessed the strength of the muscle groups responsible for
the following movements: shoulder abduction, elbow flexion
and extension, wrist dorsiflexion, finger abduction and thumb
abduction, hip flexion, knee extension, and ankle dorsiflexion
(all bilaterally), yielding a maximum score of 90 (Menon et al.,
2015). Thirty healthy volunteers recruited from the patients’
family members and faculty members served as controls. Since
the SBMA patients were all men, all of the ALS patients
and the normal controls enrolled in the study were men for
consistency. All participants were free of diabetes mellitus,
alcohol abuse, other systemic disorders or peripheral neurological
diseases.
Motor Nerve Conduction Study
The electrophysiological study was performed with the subject
lying supine in a noise-free room, and with the skin temperature
maintained between 32 and 34◦C during the experiment.
Motor nerve conduction studies were conducted according to
the standard belly to tendon technique (Pan et al., 2013).
Motor nerve conduction was investigated in the median, ulnar,
tibial, and deep peroneal nerves. Recordings were performed
with an active electrode placed on the belly of the abductor
pollicis brevis (APB), abductor digiti minimi (ADM), abductor
halluces brevis (AHB), and extensor digitorum brevis (EDB)
bilaterally and with a reference electrode placed 3 cm distal
to each active electrode. Stimulation was performed at the
wrist (7 cm from the recording electrode), elbow, and axilla
for the median nerve; at the wrist (7 cm from the recording
electrode), below the elbow, above the elbow, and axilla for
the ulnar nerve; at the ankle and popliteal fossa for the tibial
nerve; and at the ankle, below the fibular head, and above
the fibular head for the peroneal nerve. A ground electrode
was placed between the recording and stimulating electrodes.
Particular emphasis was paid to exclude the possibility of
conduction block by stimulating the tested nerves proximally
and comparing the amplitudes of the compound muscle action
potential (CMAP) responses evoked at the different stimulus
sites. Motor nerve conduction parameters, including distal
motor latency (DML) and peak-to-peak CMAP amplitude, were
analyzed.
F-Wave Study
We used the F-wave program installed in a Viking EMG machine
with a filter range of 20 Hz–3 KHz, an amplifier gain at
0.5 mV per division, and a sweep speed of 5 ms per division
for upper limb nerves and 10 ms per division for lower limb
nerves. One hundred consecutive supramaximal stimuli were
delivered bilaterally to the median and ulnar nerves at the
wrist, tibial nerve and deep peroneal nerve at the ankle with a
frequency of 1 Hz and duration of 0.1 ms. The supramaximal
intensity was 20% greater than the stimulus intensity that
was just sufficient to elicit a maximum amplitude CMAP.
According to a previous report, 100 stimuli are recommended
to adequately measure F-wave values (Rivner, 2008). Axon
reflexes were excluded from the F-wave measurements and
were defined as identical late responses with constant latencies
occurring in at least 8 of 20 stimuli that frequently preceded
and occasionally followed the F-waves (Puksa et al., 2003).
Deflections with a peak-to-peak amplitude of 40 µV and higher
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were accepted as F-waves. The following F-wave variables were
recorded: minimum F-wave latency, mean and maximum F-wave
amplitude (peak-to-peak), F-wave persistence, frequency of giant
F-waves, and frequency of patients with giant F-waves. F-wave
persistence was defined as the number of recordable F-waves
per 100 stimuli and was expressed as a percentage. An F-wave
with an amplitude exceeding the mean value plus 2 standard
deviations (SD) of the maximum F-wave amplitudes recorded
in normal subjects was considered a giant F-wave (Ibrahim
and el-Abd, 1997 ). There were no significant differences in
absolute F-wave amplitudes between the same nerves on the
left and right sides in normal controls. The critical amplitude
of a giant F-wave was calculated based on the amplitudes of
the largest F-waves recorded from the non-dominant side of
the healthy controls. In the present study, the calculated critical
amplitude for a giant F-wave was 1473.80 µV in the median
nerve, 1293.69 µV in the ulnar nerve, 1045.46 µV in the
tibial nerve, and 696.93 µV in deep peroneal nerve. This study
was approved by the Ethics Committee of Clinical Research of
Peking Union Medical College Hospital (Beijing, China) and
conformed to the principles of the Declaration of Helsinki. All
subjects gave their written informed consent to participate in the
study.
Statistical Analyses
The Kolmogorov–Smirnov test was used to test the normality
of the data. The Levene test was used to test the homogeneity
of variance between different groups. If the data were normally
distributed, a univariate ANOVA was performed for three-
group comparisons with a post hoc Newman–Keuls test. If data
were not normally distributed, a Kruskal–Wallis H test with
a post hoc Mann–Whitney U test was used. A χ2 test was
used for categorical data. The significance level was adjusted
using Bonferroni correction for multiple comparisons with
α’ < 0.0167. A spearman rank correlation test was conducted
to assess the relationship between variables. A P-value < 0.05
was considered statistically significant. If not otherwise stated,
numbers are expressed as the mean and SD. All of the
statistical tests performed were two-sided and were conducted
using SPSS for Windows, version 21.0 (SPSS, Inc., Chicago, IL,
USA).
RESULTS
The clinical profiles of the participants are summarized in
Table 1. The disease duration prior to enrollment in this study
was significantly longer in the SBMA patients in comparison with
the ALS patients. The mean ALSFRS-R score was 40.30 ± 4.04
(range 30.00–45.00), suggesting a mild-to-moderate level of
dysfunction in the ALS cohort. Muscle strength, as measured by
the MRC score, was comparable between the SBMA patients and
the ALS patients. The CAG repeat size in androgen receptor gene
of the SBMA patients in the present study was 49.00± 2.49 (range
46.00–53.00).
Conduction block or M response temporal dispersion were
not found in any of the participants enrolled in the study. The
results of nerve conduction studies of the SBMA patients, ALS
patients and normal controls are shown in Table 2. Satisfactory
motor conduction recordings were obtained in all of the SBMA
patients that were examined. For the ALS patients, CMAPs
were absent in one median nerve, one ulnar nerve, one tibial
nerve, and three deep peroneal nerves. When compared with
the controls, the CMAP amplitudes were significantly decreased,
and the DMLs were significantly prolonged in the median,
ulnar, and deep peroneal nerves of both the SBMA and ALS
patients. The CMAP amplitudes and DMLs in the tibial nerves
were comparable between the SBMA patients and the normal
controls. The CMAP amplitudes and DMLs were comparable
between the SBMA and ALS patients, except for the significantly
decreased CMAP amplitudes in the median nerves of the
ALS patients. The APB/ADM CMAP amplitude ratios were
significantly reduced in the ALS patients compared with the
SBMA patients and the normal controls. The EDB/AHB CMAP
amplitude ratios were significantly lower in the ALS patients than
in the normal controls, whereas the EDB/AHB CMAP amplitude
ratios were similar between the SBMA patients and the normal
controls.
Similar to previous investigations (Peiroglou-Harmoussi et al.,
1985), there were no correlations between F-wave amplitudes
and age, height, or sex. F-waves were absent in the right deep
peroneal nerve in two SBMA patients. For the ALS patients,
F-wave responses were absent in one median nerve, one ulnar
nerve, two tibial nerves, and six deep peroneal nerves. Table 3
TABLE 1 | Clinical profiles of the participants in the study.
Parameters SBMA (1) ALS (2) Control (3) P-value
1 vs. 3 2 vs. 3 1 vs. 2
No. 32 37 30
Age, year (range) 50.09 ± 9.42 (36.00–70.00) 49.95 ± 8.85 (31.00–69.00) 48.30 ± 10.92 (33.00–73.00) >0.05 >0.05 >0.05
Height (cm) 171.22 ± 4.98 171.59 ± 5.52 171.70 ± 4.29 >0.05 >0.05 >0.05
Duration, year (range) 8.83 ± 6.90 (2.00–30.00) 1.24 ± 0.81 (0.17–4.00) NA NA NA <0.001
Total MRC score 78.66 ± 8.67 (58.00–90.00) 76.30 ± 9.66 (51.00–90.00) NA NA NA 0.377
Upper limb MRC score 51.19 ± 6.58 (36.00–60.00) 48.65 ± 8.78 (30.00–60.00) NA NA NA 0.241
Lower limb MRC score 27.47 ± 2.87 (22.00–30.00) 28.19 ± 2.86 (21.00–30.00) NA NA NA 0.225
ALS, amyotrophic lateral sclerosis; SBMA, spinobulbar muscular atrophy; NA, not applicable. Values are mean ± SD. Values with significant differences printed in bold
characters. For comparisons of parameters between the SBMA patients, the ALS patients, and the normal controls, Bonferroni adjustment was used and α’ < 0.0167
was considered statistically significant.
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TABLE 2 | Results of nerve conduction studies.
Parameters SBMA (1) ALS (2) NC (3) P-value
1 vs. 3 2 vs. 3 1 vs. 2
DML (ms)
Median nerve 3.23 ± 0.66 3.37 ± 0.62 2.82 ± 0.37 0.001 < 0.001 0.368
Ulnar nerve 2.32 ± 0.54 2.37 ± 0.38 2.11 ± 0.27 0.010 < 0.001 0.142
Tibial nerve 3.78 ± 0.74 4.02 ± 0.86 3.60 ± 0.64 >0.05 < 0.05 >0.05
Peroneal nerve 3.64 ± 0.98 3.84 ± 1.15 3.07 ± 0.66 0.002 < 0.001 0.214
CMAP amplitude (mV)
Median nerve 10.14 ± 3.85 6.89 ± 4.77 14.31 ± 2.80 <0.001 <0.001 <0.001
Ulnar nerve 11.62 ± 3.13 10.30 ± 4.89 15.95 ± 3.02 <0.001 <0.001 0.073
Tibial nerve 13.33 ± 5.52 12.03 ± 4.61 15.31 ± 4.41 0.025 0.001 0.592
Peroneal nerve 5.84 ± 2.54 4.60 ± 2.35 7.42 ± 3.25 0.015 <0.001 0.054
APB/ADM 0.91 ± 0.36 0.65 ± 0.32 0.92 ± 0.21 0.962 <0.001 <0.001
EDB/AHB 0.47 ± 0.19 0.41 ± 0.21 0.51 ± 0.21 0.292 0.009 0.083
ADM, abductor digiti minimi; AHB, abductor halluces brevis; ALS, amyotrophic lateral sclerosis; APB, abductor pollicis brevis; CMAP, compound muscle action potential;
EDB, extensor digitorum brevis; SBMA, spinobulbar muscular atrophy. Values are mean ± SD. Values with significant differences printed in bold characters. For
comparisons of parameters between the SBMA patients, the ALS patients, and the normal controls, Bonferroni adjustment was used and α’ < 0.0167 was considered
statistically significant.
TABLE 3 | F-wave studies in upper extremity nerves.
Parameters SBMA (1) ALS (2) Control (3) P-value
1 vs. 3 2 vs. 3 1 vs. 2
Median nerve
Min F latency (ms) 24.44 ± 1.72 26.12 ± 3.03 24.72 ± 1.40 0.263 0.004 0.001
F persistence (%) 50.29 ± 25.77 53.31 ± 33.78 94.85 ± 7.07 <0.001 <0.001 0.482
Mean Famp (µV) 451.70 ± 266.59 298.13 ± 183.06 302.25 ± 99.21 <0.001 0.189 <0.001
Maximum Famp (µV) 1523.30 ± 894.59 776.36 ± 491.77 875.32 ± 327.92 <0.001 0.040 <0.001
Giant F-waves (%) 5.82 ± 12.74 0.30 ± 1.16 0.07 ± 0.33 <0.001 0.309 <0.001
Frequency of Patients with giant F-waves 25/32 6/37 3/30 <0.001 0.730 <0.001
Ulnar nerve
Min F latency (ms) 24.38 ± 2.61 25.88 ± 2.32 24.68 ± 1.56 >0.05 <0.05 <0.05
F persistence (%) 72.07 ± 18.61 75.86 ± 29.63 99.00 ± 2.31 <0.001 <0.001 0.006
Mean Famp (µV) 510.67 ± 539.58 421.75 ± 285.64 305.50 ± 84.94 <0.001 0.015 0.133
Maximum Famp (µV) 1888.33 ± 1127.67 1109.40 ± 656.90 830.70 ± 279.46 <0.001 0.008 <0.001
Giant F-waves (%) 6.64 ± 10.05 4.81 ± 15.75 0.10 ± 0.48 <0.001 <0.001 <0.001
Frequency of Patients with giant F-waves 28/32 20/37 3/30 <0.001 <0.001 0.003
ALS, amyotrophic lateral sclerosis; CMAP, compound muscle action potential; Famp, F-wave amplitude; Min F latency, minimum F-wave latency; SBMA, spinobulbar
muscular atrophy. Values are mean ± SD. Values with significant differences printed in bold characters. For comparisons of parameters between the SBMA patients, the
ALS patients, and the normal controls, Bonferroni adjustment was used and α’ < 0.0167 was considered statistically significant.
shows the results of F-wave studies performed in the upper
extremity nerves. Table 4 shows the results of F-wave studies
performed in the lower extremity nerves. The minimum F-wave
latencies in the median and ulnar nerves of the ALS patients
were significantly prolonged compared with the SBMA patients
and the normal controls. The minimum F-wave latencies in
the tibial and peroneal nerves were comparable between the
SBMA patients, the ALS patients and the normal controls. In
all nerves studied, the maximum F-wave amplitudes, frequencies
of giant F-waves, and frequencies of patients with giant F-waves
were significantly increased in the SBMA patients in comparison
with the ALS patients and the normal controls. The mean
F-wave amplitude, maximum F-wave amplitude, frequency of
giant F-waves, and the frequency of patients with giant F-waves in
both the median and peroneal nerves were comparable between
the ALS patients and the normal controls.
The number of nerves with giant F-waves in a patient seems
to be the most robust variable for differentiation of SBMA from
ALS, with an area under the curve of 0.908 (95% CI: 0.835–
0.982), showing “very good” diagnostic utility. A cut-off value of
the number of nerves with giant F-waves in a patient (≥3) for
diagnosing SBMA yielded high sensitivity and specificity: 85%
sensitivity and 81% specificity vs. ALS patients; 93% specificity
vs. normal control. The remainder of the F-wave variables had
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TABLE 4 | F-wave studies in lower extremity nerves.
Parameters SBMA (1) ALS (2) Control (3) P-value
1 vs. 3 2 vs. 3 1 vs. 2
Tibial nerve
Min F latency (ms) 45.06 ± 5.93 45.43 ± 3.91 44.37 ± 2.98 0.815 0.160 0.305
F persistence (%) 94.28 ± 14.07 95.79 ± 15.65 99.92 ± 0.46 <0.001 0.004 0.077
Mean Famp (µV) 411.96 ± 195.71 399.49 ± 299.88 271.87 ± 91.93 0.002 0.001 0.533
Maximum Famp (µV) 1054.07 ± 451.62 798.97 ± 376.37 625.48 ± 172.46 <0.001 0.002 <0.001
Giant F-waves (%) 2.49 ± 4.38 2.05 ± 11.73 0.12 ± 0.14 <0.001 0.003 <0.001
Frequency of Patients with giant F-waves 20/32 12/37 2/30 <0.001 0.010 0.013
Peroneal nerve
Min F latency (ms) 44.25 ± 7.31 44.19 ± 6.00 43.03 ± 3.44 0.624 0.159 0.672
F persistence (%) 33.14 ± 23.92 52.37 ± 25.98 46.93 ± 27.16 0.007 0.188 <0.001
Mean Famp (µV) 398.88 ± 219.74 227.46 ± 283.16 154.31 ± 91.98 <0.001 0.083 <0.001
Maximum Famp (µV) 840.35 ± 494.14 470.15 ± 334.20 370.21 ± 202.03 <0.05 >0.05 <0.05
Giant F-waves (%) 20.46 ± 28.66 5.47 ± 20.24 1.22 ± 7.13 <0.001 0.084 <0.001
Frequency of Patients with giant F-waves 22/32 10/37 3/30 <0.001 0.080 0.001
ALS, amyotrophic lateral sclerosis; CMAP, compound muscle action potential; Famp, F-wave amplitude; Min F latency, minimum F-wave latency; SBMA, spinobulbar
muscular atrophy. Values are mean ± SD. Values with significant differences printed in bold characters. For comparisons of parameters between the SBMA patients, the
ALS patients, and the normal controls, Bonferroni adjustment was used and α’ < 0.0167 was considered statistically significant.
lower diagnostic utility than did the numbers of nerves with
giant F-waves in a patient, as shown by lower area under the
curve. Tables 5 and 6 show the diagnostic performance of F-wave
parameters in SBMA.
Figure 1 shows the frequencies of subjects in each group with
giant F-waves recorded in different numbers of nerves. All of
the patients with SBMA showed giant F-waves in at least one
nerve. Accordingly, a diagnosis of SBMA is questionable if no
giant F-waves are recorded. Compared to 56.76% of the ALS
patients showing giant F-waves in only one nerve or not at
all, 70.37% of the SBMA patients presented with giant F-waves
in at least four nerves. The frequencies of patients with giant
F-waves in at least three nerves were similar between the ALS
patients and the normal controls (P = 0.270). Using a cut-
off value of six nerves presenting with giant F-waves yielded a
sensitivity of 18.25% and a specificity of 100% for differentiating
SBMA from ALS. Notably, more than half of the giant F-waves
(53.97%) were symmetrical between the left and right sides in the
SBMA patients, which was significantly higher than the 31.03%
recorded in the ALS patients (P= 0.004) and the 11.11% recorded
in the normal controls (P = 0.001). Giant F-waves typically
appeared asymmetrical in the ALS patients, which was similar
to the pattern of giant F-waves observed in the normal controls
(P = 0.171; Figure 2).
TABLE 5 | Diagnostic performance of F-wave parameters in upper extremity nerves in spinobulbar muscular atrophy.
Vs. ALS Vs. control
Parameters Cut-off
value
Sen (%) Spe (%) AUC (95% CI) Cut-off
value
Sen (%) Spe (%) AUC (95% CI)
Median nerve
Min F latency 25.3 ms 76.7 56.3 0.644 (0.555–0.725) P = 0.001 24.1 ms 53.3 73.3 0.609 (0.516–0.697) P = 0.039
F persistence 86.0% 93.7 24.7 0.537 (0.450–0.623) P = 0.456 83.0% 90.6 91.7 0.968 (0.920–0.991) P < 0.001
Mean Famp 269.0 µV 78.1 54.8 0.701 (0.617–0.776) P < 0.001 509.0 µV 32.8 100 0.675 (0.580–0.756) P < 0.001
Max Famp 1057 µV 70.3 76.7 0.782 (0.705–0.859) P < 0.001 1131 µV 65.6 80 0.751 (0.666–0.824) P < 0.001
Giant F-wave 1.09% 43.8 93.2 0.686 (0.601–0.720) P < 0.0010.001 1.14% 43.7 98.3 0.704 (0.615–0.782) P < 0.001
Ulnar nerve
Min F latency 24.8 ms 70.0 69.0 0.701 (0.615–0.778) P < 0.001 24.5 ms 63.3 56.7 0.579 (0.486–0.669) P = 0.134
F persistence 92% 82.8 54.8 0.637 (0.551–0.718) P = 0.005 95.3% 95.3 90.0 0.981 (0.939–0.997) P < 0.001
Mean Famp 296 µV 75.0 41.1 0.575 (0.487–0.659) P = 0.129 373 µV 57.8 81.7 0.707 (0.618–0.785) P < 0.001
Max Famp 1352 µV 64.1 72.6 0.730 (0.648–0.803) P < 0.001 1289 µV 65.6 95 0.855 (0.780–0.912) P < 0.001
Giant F% 1.03% 65.6 72.6 0.678 (0.593–0.756) P < 0.001 1.0% 65.6 96.7 0.815 (0.737–0.879) P < 0.001
ALS, amyotrophic lateral sclerosis; AUC, area under the curve; CI, confidence interval; Max Famp, maximum F-wave amplitude; Min F latency, minimum F-wave latency;
Sen, sensitivity; Spe, specificity.
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TABLE 6 | Diagnostic performance of F-wave parameters in lower extremity nerves in spinobulbar muscular atrophy.
Vs. ALS Vs. control
Parameters Cut-off
value
Sen (%) Spe (%) AUC (95% CI) Cut-off
value
Sen (%) Spe (%) AUC (95% CI)
Tibial nerve
Min F latency 44.9 ms 56.9 58.6 0.550 (0.459–0.638) P = 0.339 47.8 ms 25.9 89.3 0.510 (0.415–0.605) P = 0.858
F persistence 99% 33.3 80.6 0.569 (0.480–0.655) P = 0.079 99% 33.3 96.4 0.651 (0.557–0.737) P < 0.001
Mean Famp 479 µV 30 89.2 0.533 (0.429–0.635) P = 0.581 419 µV 40 89.3 0.669 (0.575–0.753) P < 0.001
Max Famp 970 µV 51.7 77.8 0.678 (0.591–0.757) P < 0.001 818 µV 68.3 82.1 0.797 (0.712–0.866) P < 0.001
Giant F-wave 1.0% 43.3 87.5 0.636 (0.548–0.718) P < 0.001 1.0% 43.3 98.2 0.698 (0.606–0.780) P < 0.001
Peroneal nerve
Min F latency 38.3 ms 22.0 89.4 0.516 (0.421–0.609) P = 0.781 45.5 ms 40.0 86.7 0.533 (0.436–0.629) P = 0.585
F persistence 49% 76.9 63.2 0.701 (0.611–0.781) P < 0.001 46.0% 75 53.3 0.640 (0.543–0.728) P = 0.008
Mean Famp 268 µV 69.2 86.8 0.811 (0.729–0.877) P < 0.001 201 µV 82.7 88.3 0.877 (0.802–0.932) P < 0.001
Max Famp 586 µV 65.4 76.5 0.742 (0.654–0.818) P < 0.001 543 µV 71.2 83.3 0.817 (0.733–0.884) P < 0.001
Giant F% 3.1% 51.9 91.2 0.697 (0.606–0.777) P < 0.001 1.8% 53.8 98.3 0.750 (0.660–0.827) P < 0.001
ALS, amyotrophic lateral sclerosis; AUC, area under the curve; CI, confidence interval; Max Famp, maximum F-wave amplitude; Min F latency, minimum F-wave latency;
Sen, sensitivity; Spe, specificity.
FIGURE 1 | Histogram of frequencies of subjects exhibiting giant
F-waves in different numbers of nerves in the spinobulbar muscular
atrophy (SBMA) patients, the amyotrophic lateral sclerosis (ALS)
patients, and the normal controls. Ordinate, frequency of subjects with
giant F-waves in different numbers of nerves. Abscissa, number of nerves with
giant F-waves.
Correlations between the numbers of giant F-waves and
clinical variables were performed. The sum of frequencies of
giant F-waves of eight nerves in four limbs was presumed to be
an appropriate measure in motor neuron disease characterized
by diffuse loss of motoneurons. For the ALS patients, no
correlations were found between the pooled frequencies of
giant F-waves (22.38 ± 55.37%, range 0–303.00%) and disease
FIGURE 2 | Histogram of frequencies of giant F-waves recorded
symmetrically between the left and right sides in the spinobulbar
muscular atrophy (SBMA) patients, the ALS patients, and the normal
controls. Ordinate, frequency of giant F-waves recorded symmetrically
between the left and right sides. The frequency of symmetrical giant F-waves
between the left and right sides in the SBMA patients was significantly higher
than those in the ALS patients (P = 0.004) and the normal controls
(P = 0.001). While the frequencies of symmetrical giant F-waves were
comparable between the ALS patients and the normal controls (P = 0.171).
∗P < 0.05.
durations before electrophysiological examinations (r = 0.107,
P = 0.529), and the severity of the disease as determined by
the total MRC scores (r = 0.157, P = 0.354), or the ALSFRS-
R scores (r = 0.020, P = 0.909). Likewise, there were no
correlations between the pooled frequencies of giant F-waves
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(71.59 ± 47.92%, range 1.49–148.97%) and the disease durations
(r = 0.162, P = 0.418) and the total MRC scores (r = −0.052,
P = 0.796) in the SBMA patients. We divided the SBMA cohort
into early (<5 years) versus chronic cases (≥5 years) according
to the disease duration. There was no significant difference
in the pooled frequencies of giant F-waves between the early
cases (54.50 ± 40.68%) and the chronic cases (75.47 ± 49.42%,
P = 0.314).
DISCUSSION
The electrodiagnostic features of both the SBMA and ALS
patients are consistent with a progressive degeneration of
anterior horn cells. These electrodiagnostic features included
mildly prolonged DMLs and F-wave latencies, reduced CMAP
amplitudes, decreased F-wave persistence, increased F-wave
amplitudes, and increased frequencies of giant F-waves, when
compared to the normal controls. Compared to the ALS patients,
CMAP amplitude abnormalities were less frequent and less
pronounced in the SBMA patients. The APB/ADM CMAP
amplitude ratio in the ALS patients was reduced significantly
compared to that in the normal controls, which is in agreement
with the split-hand sign in ALS patients (Eisen and Kuwabara,
2012). However, the APB/ADM CMAP amplitude ratio in
the SBMA patients was comparable to that in the normal
participants, suggesting a generalized and non-selective process
of motoneuron loss. The EDB/AHB CMAP amplitude ratios
were significantly decreased in the lower limbs of the ALS
patients compared to those in the normal controls, suggesting
preferential involvement of motoneurons innervating EDB in
ALS. Another possible explanation was that in tibial nerve
conduction studies, the AHB CMAP included activity from
other foot muscles recorded by the reference electrode, whereas
in the CMAP recording of EDB, the contribution by the
reference electrode was much smaller (Nandedkar and Barkhaus,
2007; Barkhaus et al., 2011). The possible pathophysiological
mechanisms of the extended minimum F-wave latencies in the
median and ulnar nerves of ALS patients involve preferential
loss of fast conducting fibers, axonal degeneration that slows the
propagation of depolarization before conduction is lost entirely,
or proximal axonal swellings that slows F-wave turnaround
(Carpenter, 1968; Argyriou et al., 2006). While SBMA affects
the anterior horn cells diffusely and non-selectively (Ferrante
and Wilbourn, 1997; Finsterer, 2010). In ALS patients, 52.70%
of the upper limbs were clinically symptomatic, whereas only
31.08% of the lower limbs were clinically affected. This may
account for the comparable minimum F-wave latency in the
lower extremity nerves between the SBMA patients, the ALS
patients and the normal controls. The amplitudes of F-waves are
indices of motor unit size and motoneuron excitability (Eisen
and Odusote, 1979; McNeil et al., 2013). In anterior horn cell
disorders, surviving motor neurons compensate for functional
motor unit loss by increasing the size of their motor units through
axonal sprouting and reinnervating denervated muscle fibers.
The increased mean F-wave amplitudes are probably caused
by a higher proportion of large motor units contributing to
F-waves (Ibrahim and el-Abd, 1997). The generation of giant
F-waves in patients with anterior horn cell disorders may be
attributed to axonal sprouting and subsequent reorganization of a
muscle’s innervation (Ibrahim and el-Abd, 1997). Other possible
mechanisms have been discounted, such as an entire motoneuron
pool responding to a stimulus recurrently, an enhanced H-reflex,
a repetitive muscle response to an orthodromic motor impulse,
and an axon reflex (Ibrahim and el-Abd, 1997). Autopsies
showed involvement of the corticospinal tract in 50% to
66% of ALS patients who showed no UMN signs during life
(Ince et al., 2003). Consequently, the supraspinal influences
on F-waves in patients with LMND ALS cannot be ruled
out.
Polyglutamine expansion of the androgen receptor causes
SBMA through poorly defined cellular and molecular etiology.
High levels of circulating androgens have a role in the
pathogenesis of this ligand-dependent neurodegenerative disease
(Chua and Lieberman, 2013). Threshold tracking transcranial
magnetic stimulation techniques have established normal
cortical excitability in SBMA, inferring a lack of significant
cortical involvement in this disease (Vucic and Kiernan,
2008). SBMA results from the dysfunction and degeneration
of specific motor and sensory neurons (Beitel et al., 2005).
The pathogenetic mechanisms of ALS involve accumulation
of protein aggregates, oxidative stress, glutamate-induced
excitotoxicity, glial dysfunction, neuroinflammation, apoptosis,
mitochondrial dysfunction, autophagy, and metal imbalances
(Wiedemann et al., 2002; Lederer et al., 2007; Figueroa-Romero
et al., 2012). Cortical dysfunction contributed to the pathogenesis
of ALS (Menon et al., 2014). Glutamate-mediated cortical
hyperexcitability may underlie the different rate of degeneration
of motoneurons in ALS (Menon et al., 2014). Compared with
ALS, SBMA typically has a relatively slower progression. The
differences in F-wave characteristics between the SBMA and
ALS patients may be attributed to the distinct pathogenesis and
the competing effects of degeneration and regeneration within
the motor unit. When a muscle is partly denervated, the muscle
fibers that have retained innervation may hypertrophy, and
collateral reinnervation may take place (McComas et al., 1971).
An increased number of markedly hypertrophic fibers were
consistently observed in SBMA patients, whereas this feature
is not common in ALS patients (Chahin and Sorenson, 2009).
Motor neurons are lost as motor neuron disease progresses,
and this can be demonstrated by neurophysiological measures
that include CMAP amplitudes, motor unit estimates, and
motor unit number indices (Neuwirth et al., 2010). Given the
large difference in disease duration between SBMA and ALS,
the relative paucity of giant F-waves in ALS likely reflects a
decreased efficiency of the burden of reinnervation in surviving
motoneurons. Therefore, the diagnosis of SBMA should be
questioned if no giant F-waves are recorded. The significantly
increased frequency of giant F-waves in SBMA suggests that an
increased number of giant F-waves may indicate a decreased
rate of the degenerative process. Although electromyography
detected diffused neurogenic lesion in both the SBMA and ALS
patients. Compared with the ALS patients, giant F-waves were
liable to appear in more nerves and symmetrically in SBMA
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patients. In SBMA, the LMNs are affected diffusely and non-
selectively, whereas in ALS, the rate of motor unit loss differs
according to the nerve and muscle, as well as the site of disease
onset (Baumann et al., 2012). The present study demonstrated
that the number of nerves with giant F-waves in a patient was
the best index to diagnose SBMA among the multiple F-wave
parameters. In our study, the frequencies of giant F-waves were
not correlated with disease duration. In addition, the pooled
frequency of giant F-waves was similar between the chronic
SBMA patients and the early SBMA patients. In other words,
this finding supported the clinical utility of giant F-waves in
discriminating SBMA from ALS even in the early disease course.
Although the SBMA patients had a long duration from disease
onset, this did not seem to affect our analyses.
Of note, the mean F-wave amplitude, maximum F-wave
amplitude, frequency of giant F-waves, and the frequency of
patients with giant F-waves in the median and deep peroneal
nerves were comparable between the ALS patients and normal
controls. This similarity may be related to the differential
involvement of the upper and lower limb muscles in ALS
patients (Menon et al., 2013b; Simon et al., 2015). In ALS,
there are disparities in muscle activation during physical activity,
cortical modulation, or local spinal modulation between different
muscle pairs, such as APB and flexor pollicis longus, APB and
ADM, or tibialis anterior and soleus (Menon et al., 2013a, 2014;
Shibuya et al., 2013; Simon et al., 2015). Previous studies of
ALS demonstrated that LMN degeneration in APB or EDB is
faster than that in ADM (Kuwabara et al., 1999; Baumann et al.,
2012). The dissociated involvement of the small hand muscles
in which APB motoneurons are more severely affected than
ADM motoneurons, which is termed the “split-hand” syndrome,
reflects part of pathophysiology in ALS (Kuwabara et al., 1999).
In the present study, preferential involvement of APB and EDB
in ALS was indicated.
There are several limitations to our study. The occurrence
of giant F-waves has been demonstrated in other anterior horn
cell diseases (Ibrahim and el-Abd, 1997). Therefore, disease
control group including patients with other LMN syndrome,
such as adult onset spinal muscular atrophy, or patients with
sequelae following paralytic poliomyelitis, could be included in
further study. The number of SBMA and ALS patients included
in the present study was too small to draw a generalizable
conclusion. Further studies with larger sample sizes are necessary
to validate our present findings. In addition, muscle weakness
in SBMA patients is usually more severe in the proximal
muscles (Ferrante and Wilbourn, 1997). Accordingly, F-waves
recorded from small muscles in the distal extremities cannot
thoroughly reflect the pathological changes in SBMA. This
study was based on a series of 100 F-waves in each nerve,
which resulted in a large number of stimuli that were delivered
in a single subject. Further study is needed to determine an
adequate sample size of F-waves for group comparisons of
giant F-waves. Another potential limitation of the study was
that the upper range of disease duration in the ALS patients
was 4 years. Giant F-waves may be more common in ALS
patients with a longer disease duration and it is difficult to
differentiate ALS patients with a long duration from SBMA
patients. Therefore, additional studies that include ALS patients
with longer disease durations are needed. Finally, most SBMA
patients showed a longer CAG repeat (≥47), while only two
SBMA patients showed a shorter CAG repeat (<47) in the present
study. This was consistent with a motor-dominant phenotype
of the SBMA patients in our study, such as clinical symptoms
of muscle weakness and atrophy, decreased CMAP values, and
evidence of widespread acute and chronic motor axon loss in
electromyography (Suzuki et al., 2008). Further studies enrolling
larger numbers of SBMA patients particularly SBMA patients
with a shorter CAG repeat (<47) are needed to investigate
the value of F-waves in distinguishing two subgroups of SBMA
patients.
Based on the findings of the present study, a significant
increase in the frequency of giant F-waves, especially in the
median and deep peroneal nerves, or giant F-waves recorded
from multiple nerves (≥3) or symmetrically between the left
and right sides in male patients with LMN syndromes, are
highly suggestive of SBMA. In these cases, genetic testing is
recommended, even when the typical clinical features of SBMA
are absent.
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